Syon Capital’s Sarepta Therapeutics SRPT Stock Holding History

Syon Capital’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-4,112	Closed	-$500K	–	657
2024 Q4	$500K	Buy	+4,112	New	+$504K	0.05%	283

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Syon Capital's SRPT Position: Q1 2025 in Review

Syon Capital sold out of Sarepta Therapeutics (SRPT) in Q1 2025, closing a stake of 4,112 shares — an estimated $500K sold.

Syon Capital first reported a position in SRPT in Q4 2024 and held it in 1 quarter. The position peaked at $500K in Q4 2024. 430 funds tracked by Wall St. Rank hold SRPT as of Q1 2025.

Syon Capital reported no remaining Sarepta Therapeutics position as of Q1 2025 after selling out during the quarter.
Syon Capital sold 4,112 Sarepta Therapeutics shares in Q1 2025, an estimated $500K.
Syon Capital first reported a position in Sarepta Therapeutics in Q4 2024 and held it in 1 quarter.
Syon Capital's Sarepta Therapeutics position peaked at $500K in Q4 2024.
430 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2025.

Based on Syon Capital's 13F filing for Q1 2025, filed 15 May 2025.